VIDA expands board, announcing Erkan Akyuz as independent director

Published on: October 04, 2019

Coralville, IA (October 4, 2019) — VIDA Diagnostics, Inc. (“VIDA”), the leader in AI-powered lung imaging analysis, today announced the appointment of Erkan Akyuz as to help guide the company’s growth initiatives with differentiated healthcare IT leadership and market expertise.

“I am energized to join VIDA’s Board of Directors,” stated Erkan Akyuz, President and CEO at Rhapsody and Corepoint Health. “VIDA has the potential to significantly expand its presence in the healthcare AI market and bring precise, personalized information to care providers. I’m looking forward to working with VIDA’s exceptional team as they continue their growth trajectory.”

“I am thrilled to welcome Mr. Akyuz to VIDA’s Board of Directors,” said Susan A. Wood, PhD, President and CEO of VIDA. “His expertise in leading healthcare IT organizations and market understanding is a perfect fit with our shared vision of expanding access to our innovative, AI- powered clinical solution that improves the lives of pulmonary patients and populations."

Around the web

Cardiovascular Business

Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business

‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business

FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer.